Genistein induces growth inhibition in various human cancer cell lines but its mechanism of action remains unknown. This study determined whether the effect of genistein is mediated via suppression of cyclo-oxygenase (COX)-2 protein, and elucidated the mechanism of action of this effect in the human gastric cancer cell line BGC-823. Genistein treatment inhibited cell proliferation and induced apoptosis in a dose-and time-dependent manner; Western blotting analysis indicated a significant dose-dependent decrease in COX-2 protein levels. Genistein treatment exerted a significant inhibitory effect on activation of the transcription factor nuclear factor kB (NF-kB). Additionally, the NF-kB inhibitor pyrrolidine dithiocarbamate caused a reduction in COX-2 protein levels and NF-kB activation, similar to the effect of genistein. Suppression of COX-2 protein may be important for the antiproliferative and proapoptotic effects of genistein in BGC-823 cells, and these effects may be partly mediated through the NF-kB pathway.
Introduction
Gastric cancer is common in Asia and, given its high incidence (up to 47.6 cases per 100 000 men), lack of early screening and resistance to anticancer therapies, cancer prevention is an alternative and promising strategy. 1 The aim of cancer chemoprevention is to block, reverse or delay carcinogenesis by targeting key molecular abnormalities using pharmacological or nutritional agents. 2 Genistein, a natural isoflavone found in soybean products, is regarded as a potential chemopreventive and chemotherapeutic nutritional agent. Genistein decreases the proliferation of various cancer cell lines in vitro, including those of the prostate, breast, colon, lung and ovary, 3 -7 but few studies have investigated the actions of genistein in gastric cancer cells.
Cyclo-oxygenase (COX)-2 is an inducible isozyme of COX that catalyses the formation
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of prostaglandins from arachidonic acid. Increasing evidence from animal models and human studies has demonstrated that COX-2 plays a crucial role in carcinogenesis and cancer progression. 8 Increased levels of COX-2 protein are observed in a variety of cancers including breast, prostate, colon, lung and stomach cancers. 9 -13 The suppression of COX-2 is, therefore, regarded as a promising approach to cancer prevention.
The promoter region of the human PTGS2 gene (prostaglandin endoperoxide synthase-2, which encodes COX-2) contains two putative binding sites for the eukaryotic transcription factor, nuclear factor κB (NF-κB). 14 NF-κB has been shown to upregulate COX-2 in diverse cell types and is an important component of the intracellular signalling pathway responsible for inducing PTGS2 expression. 15, 16 Interestingly, genistein has been shown to inhibit the activity of NF-κB in T-cell lymphomas. 17 The present study was designed to determine whether the growth-inhibitory effect of genistein on the human gastric cancer cell line BGC-823 was associated with an alteration in COX-2 protein levels, and to elucidate the mechanism of action of genistein.
Materials and methods
CELL CULTURE
Human gastric cancer BGC-823 cells (XiangYa Central Experiment Laboratory of Central South University, Changsha, China) were maintained in RPMI 1640 (Gibco ® BRL Life Technologies, Gaithersburg, MD, USA) containing 10% fetal bovine serum, 100 IU/ml penicillin and 100 µg/ml streptomycin, at 37°C with 5% carbon dioxide in air. 
DETERMINATION OF APOPTOSIS
Morphological determination
WESTERN BLOT ANALYSIS OF COX-2 PROTEIN LEVELS
Cells were plated at a density of 1 × 10 5 per well in six-well plates and treated with genistein (10, 50, 100 or 200 µM) for 72 h. Cells were collected and proteins were extracted using a lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM saline, 0.1% sodium dodecyl sulphate (SDS), 1% NP-40 (Tergitol-type nonyl phenoxypolyethoxylethanol), and 1 × protease inhibitors (Roche Applied Science, Indianapolis, IN, USA). Protein (15 µg per lane) was separated by 12% SDS-polyacrylamide gel electrophoresis and transferred to an Osmonics polyvinylidene fluoride membrane (ColeParmer, Vernon Hills, IL, USA). The membrane was blocked for 1 h at room temperature in a blocking buffer containing 3% bovine serum albumin and incubated with a rabbit polyclonal anti-COX-2 antibody (1 : 500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in the blocking buffer overnight at 4°C. After incubation with the primary antibody, the membranes were washed three times for 15 min with 20 mM Tris-buffered saline and 0.1% Tween 20 (TBST). The membrane was then incubated with a horseradish peroxidase (HRP)-conjugated goat antirabbit secondary antibody (1 : 1000 dilution; ZhongShan Golden Bridge Biotechnology, Beijing, China) for 1 h at room temperature, then washed a further three times for 15 min with TBST. Specific proteins were detected using an enhanced chemiluminescence kit (Pierce Protein Research Products, Rockford, IL, USA) according to the manufacturer's instructions. The same membrane was then used to detect β-actin protein using a mouse monoclonal anti-β-actin antibody (1 : 1000 dilution; Beyotime Biotech, Jiangsu, China) and a goat antimouse immunoglobulin (Ig)G secondary antibody (ZhongShan Golden Bridge Biotechnology), using the method described above. and placed on a shaking platform for 15 min at 4°C to disrupt the nuclear membrane. Nuclear extracts were collected after ultracentrifugation at 135 000 g for 5 min at 4°C, aliquoted and immediately frozen. All extracts were stored at -70°C until they were used.
DETERMINATION OF NF-κB ACTIVITY
Preparation of nuclear extracts
NF-kB activity assay
Activity of NF-κB was detected by an enzyme-linked immunosorbent assay-based approach, according to the method of Jin et al. 18 Briefly, two single-stranded oligonucleotide chains derived from the human PTGS2 promoter region with homology to the putative NF-κB binding sites were synthesized (5′-AGT TGA GGG GAC TTT CCC AGG CC-(C)34-C-3′ [the 3′ end was biotinylated]; 5′-GCC TGG GAA AGT CCC CTC AAC T-3′). Oligonucleotides were mixed in a 1 : 1 ratio, denatured at 94°C for 10 min and allowed to anneal at room temperature overnight. The next day, the probes were linked to streptavidin-coated 96-well plates for 1 h at 37°C. Plates were washed twice with 0.01 M PBS containing 0.1% Tween-20 (PBST) to remove the excess probe and washed once with 0.01 M PBS, pH 7.4, alone. Nuclear extracts (100 µl) were added to the wells and incubated at 37°C for 1 h. After washing three times for 15 min in PBST, 100 µl of mouse antihuman NF-κB monoclonal antibody (1 : 1000 dilution; Santa Cruz Biotechnology) was added to each well and incubated for 1 h at 37°C. After washing three times for 15 min in PBST, HRPconjugated goat antimouse IgG (1 : 2000 dilution; Santa Cruz Biotechnology) was added to the wells for 1 h at room temperature, then washed a final three times for 15 min in PBST. Finally, 100 µl of 0.1 mg/ml 3,3′,5,5′-tetramethylbenzidine was added to each well for 10 min before then adding 100 µl of stopping solution (2 M sulphuric acid). The optical density at 490 nm was read using an autoreader (BioTek).
EFFECT OF NF-kB INHIBITOR ON COX-2 PROTEIN LEVEL AND NF-kB ACTIVITY
Cells were plated at a density of 1 × 10 5 into each well in six-well plates and incubated for 24 h. To assess the effect of the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) on BGC-823 cells, PDTC was then added to the wells at different concentrations (10, 25 or 50 µM) and incubation was continued for a further 12 h. COX-2 protein level and NF-κB activity were detected using the methods described above.
STATISTICAL ANALYSES
All statistical analyses were carried out using SPSS ® statistical software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . All data are presented as mean ± SD. Statistical analyses were performed using analysis of variance followed by Dunnett's t-test. A Pvalue < 0.05 was considered to be statistically significant.
Results
Incubation with 0, 5, 10, 25, 50, 100 or 200 µM of genistein for 24, 48 or 72 h inhibited proliferation of BGC-823 cells in dose-and time-dependent manners (Fig. 1) 
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condensation and aggregation of nuclear chromatin and the formation of apoptotic bodies ( Fig. 2A) . Flow cytometric analysis showed that the apoptotic rate was 2.3 ± 0.2% in control cells. After treatment with 10, 50, 100 or 200 µM genistein for 72 h, the apoptotic rate increased to 8.1 ± 1.0%, 19.3 ± 1.7%, 25.2 ± 1.5% and 37.2 ± 0.9%, respectively (P < 0.05, n = 4) (Fig. 2B) .
Genistein suppressed the production of COX-2 protein in a dose-dependent manner (Fig. 3A) . In addition, NF-κB DNA-binding activity was significantly decreased in BGC-823 cells by treatment with 50, 100 or 200 µM genistein for 72 h (P < 0.05 or P < 0.01; Fig. 3B ).
To demonstrate that the NF-κB signalling pathway is directly involved in the regulation of COX-2 in BGC-823 cells, whether the NF-κB inhibitor PDTC could suppress COX-2 protein levels was investigated. As shown in Fig. 4A , treatment with PDTC at concentrations of 10, 25 and 50 µM for 12 h significantly reduced COX-2 protein levels in BGC-823 cells, compared with controls (P < 0.05). In addition, NF-κB DNA-binding activity was suppressed significantly by PDTC treatment compared with controls (P < 0.05 or P < 0.01; Fig. 4B ).
Discussion
The present study found that genistein inhibited cell proliferation and induced Several mechanisms have been proposed for the anticancer activities of genistein. These include blocking the activities of protein tyrosine kinase, topoisomerase II and matrix metalloprotein, arresting cell growth and the cell cycle at G 2 /M, and preventing invasion and angiogenesis. 21 The molecular targets of genistein in gastric cancer cells have not been well studied, however. Evidence has shown a role for COX-2 in gastrointestinal carcinogenesis. An in vitro study reported increased COX-2 protein levels in 46 of 107 gastric adenocarcinoma cases and that this may contribute to gastric cancer by promoting angiogenesis and inhibiting apoptosis. 22 In addition, COX-2 has been shown to be associated with 
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lymphangio genesis and lymph node metastasis in gastric cancer patients. 23 Clinical studies have also indicated that COX-2 inhibitors can reduce cancer risk and promote tumour regression in patients with gastrointestinal cancers. 24 The present study demonstrated that genistein suppressed COX-2 protein in a dose-dependent manner. This was in agreement with the observation described by Lee et al. 25 who studied another flavouring agent, curcumin (the main curcuminoid found in turmeric): genistein and curcumin therefore appear to have similar suppressive effects on COX-2 in cancer cells.
In order to identify the mechanism by which genistein downregulated COX-2, the effect of genistein on PTGS2 promoter activity was studied. The PTGS2 promoter region contains several potential binding sites, but the transcription factors involved in PTGS2 gene regulation depend on the cell type and the stimulus involved. NF-κB is widely responsible for the regulation of PTGS2 gene expression in various cells in response to numerous stimuli. 26, 27 It has been demonstrated that NF-κB acts as a positive regulator of PTGS2 transcription in inflammation-associated cancer. 28 Huang et al. 29 demonstrated that the expression and activity of NF-κB/p65 were significantly correlated with COX-2 protein levels, providing indirect proof of the NF-κB regulation of PTGS2. It was shown, in the present study, that genistein strongly inhibited the DNA binding activity of NF-κB in BGC-823 cells. This is in accordance with a previous study that showed that genistein treatment could modulate NF-κB DNA binding activity in prostate, breast, head and neck, and pancreatic cancer cells. 30 In addition, in the present study, treatment with PDTC (an inhibitor of NF-κB) suppressed COX-2 protein and NF-κB activation. These findings indicate that genistein may inhibit COX-2 protein levels in BGC-823 cells by suppressing the activation of NF-κB.
In conclusion, the results of the present study strongly support the antiproliferative and proapoptotic effects of genistein in BGC-823 gastric cancer cells. This effect was partly mediated by inactivation of the NF-κB signalling pathway, resulting in reduced levels of COX-2 protein. These results suggest that genistein has potential chemopreventive activity with respect to gastric cancer.
